Users discuss waiting for new hair loss treatments and share struggles with side effects from current options like Minoxidil and Finasteride. They express hope for Pyrilutamide and CosmeRNA to provide better solutions.
The conversation is about the anticipated release timeline for a hair loss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.
A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.
A dermatologist prescribed Betnovate scalp, a corticosteroid, for a 21-year-old male's hair loss due to DHT. The individual is considering using Nizoral shampoo, topical finasteride, a derma roller, and minoxidil, but is unsure about the effectiveness of two other products suggested by the dermatologist.
The user has been using topical finasteride for seven months and minoxidil for three years, with added tretinoin gel for ten months, and is experiencing continuous shedding without signs of regrowth. They are questioning if the amount of shedding is normal at this stage of treatment and if there's a correlation between finasteride response and the rate of hair loss.
A user's results after using finasteride (1.25mg/day) for one year, which included improvements to their hair and skin as well as some side effects such as decreased libido and watery semen. They also mentioned they stopped taking creatine around the same time.
Pyrilutamide, a potential hair loss treatment, and how it compares to existing treatments such as Minoxidil, Finasteride and RU58841. Real-world results are being discussed to determine its effectiveness.
Yokohama University and Dr. Fukuda plan human hair multiplication trials in 2023. Users express hope for future hair cloning treatments over current hair transplants.
The conversation is about sourcing and using topical melatonin for retrograde alopecia. Users discuss purchasing options and potential benefits for hair growth.
Nearly 40% of adults with alopecia areata achieved at least 80% scalp hair coverage after 52 weeks of taking OLUMIANT® 4-mg. The conversation distinguishes this success from androgenetic alopecia, which is a different type of hair loss.
A user experienced mild side effects from 0.5mg finasteride daily, including increased estradiol and minor gynecomastia. They are considering taking a low dose of exemestane to reduce estrogen levels.
Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.
Finasteride was intentionally developed to treat BPH and later approved for male pattern baldness (MPB) due to its 5AR inhibition effects. The delay in MPB approval was due to concerns about off-label use for female hirsutism and the prioritization of treating a more debilitating condition.
The conversation is about someone considering using Minoxidil combined with a weak antiandrogen for hair loss, but is concerned about potential increased hair loss if they stop using Minoxidil. They are seeking others' experiences with stopping Minoxidil and the effects on their hair.
A user experienced severe side effects, including symptoms of congestive heart failure, after using excessive doses of minoxidil for beard growth. They stopped using it due to financial reasons, but still suffer from lingering symptoms and are advised to seek medical attention.
A regimen for hair loss, which includes using Nizoral shampoo twice daily, Minoxidil foam from the can, 5mg of Propecia crushed and snorted on weekends, and dermastamping directly to the head of the penis. Replies discuss potential sides and other treatments, as well as the idea that confidence is more attractive than hair.
A user experienced severe side effects, including erectile dysfunction and testicular pain, after taking finasteride for hair loss. They recommend sticking to minoxidil and biotin and avoiding finasteride due to potential risks.
A 16-year-old is experiencing severe hair thinning and wants to start finasteride but is advised to wait until at least 20. In the meantime, minoxidil is suggested as an alternative.
A mid-30s individual is experiencing hair loss at the front and temples but not the crown, and is seeking affordable treatments. They have ordered pumpkin seed oil capsules due to cost and side effects concerns with official treatments.
Minoxidil non-responders may benefit from using minoxidil sulfate due to reduced sulfotransferase activity in their scalps. Users are encouraged to share their experiences with minoxidil sulfate.
A 27-year-old male physician improved hair density using minoxidil 5% foam and finasteride 1mg every other day, with initial sexual side effects that subsided. He recommends trying finasteride for a year but warns against dutasteride due to potential liver effects.
A 23-year-old male experienced nipple sensitivity after starting finasteride for hair loss and stopped using it due to concerns about gynecomastia. He is worried about the risk of developing gynecomastia if he resumes finasteride, especially with plans to increase muscle mass.
PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.
Clascoterone is considered overhyped and not as effective as finasteride or dutasteride, but it may be useful as a supportive treatment in combination with other therapies. Users express skepticism about its effectiveness compared to clinical trials, with some suggesting it could be beneficial for those who cannot tolerate other treatments.
The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.
Oral dutasteride and oral minoxidil are recommended for hair regrowth, with topical treatments being less effective. Stopping treatment results in losing any regrowth achieved.
The conversation discusses the effectiveness of using 2.5 mg Dutasteride daily versus combining 0.5 mg Dutasteride with 150 mg RU58841 for reducing scalp DHT. Opinions vary, with some users recommending lower doses of Dutasteride and cautioning against RU58841 due to potential side effects.